EP3733203A1 - Agent prophylactique et/ou agent thérapeutique contre la cataracte, composition médicinale pour prévenir et/ou traiter la cataracte, utilisation d'un activateur de ppar pour produire ces derniers, et collyre - Google Patents

Agent prophylactique et/ou agent thérapeutique contre la cataracte, composition médicinale pour prévenir et/ou traiter la cataracte, utilisation d'un activateur de ppar pour produire ces derniers, et collyre Download PDF

Info

Publication number
EP3733203A1
EP3733203A1 EP18893830.2A EP18893830A EP3733203A1 EP 3733203 A1 EP3733203 A1 EP 3733203A1 EP 18893830 A EP18893830 A EP 18893830A EP 3733203 A1 EP3733203 A1 EP 3733203A1
Authority
EP
European Patent Office
Prior art keywords
cataract
agent
acid
ppar
ppar activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18893830.2A
Other languages
German (de)
English (en)
Other versions
EP3733203A4 (fr
Inventor
Masaya OKI
Fumito KANADA
Kazuma KAMATA
Yoshihiro TAKAMURA
Seiji MIYAKE
Masaru INATANI
Hiroyuki Uchida
Miho NOGATA
Masatomo Kato
Koushi Fujisawa
Shinji Takaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
University of Fukui NUC
Original Assignee
Santen Pharmaceutical Co Ltd
University of Fukui NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, University of Fukui NUC filed Critical Santen Pharmaceutical Co Ltd
Publication of EP3733203A1 publication Critical patent/EP3733203A1/fr
Publication of EP3733203A4 publication Critical patent/EP3733203A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an agent for prevention and/or therapeutic treatment of cataract, a pharmaceutical composition for prevention and/or therapeutic treatment of cataract, use of a PPAR activator for production of the agent or the composition, and an ophthalmic agent.
  • Cataract is a disease that creates an opaque (e.g., milky) area in the crystalline lens and thereby causes decreased vision.
  • an opaque area e.g., milky
  • the opaque area occurs in the nucleus, cortex, posterior capsule, and/or the like of the crystalline lens.
  • age-related cataract is the most prevalent type.
  • age-related cataract the number of patients increases as the age increases.
  • diabetic cataract is prevalent among people in their 60s and younger.
  • Diabetic cataract can also occur in the younger generation.
  • Cataract can be therapeutically treated, for example, by surgery or by administration of a preventive agent or a therapeutic agent.
  • a preventive agent and therapeutic agent include agents that contain glutathione or pirenoxine (see Non-patent Literatures 1 and 2).
  • the present invention was made in view of the above conventional issue, and an object thereof is to provide an agent for prevention and/or therapeutic treatment of cataract that acts by a different mechanism from conventional agents, a pharmaceutical composition for prevention and/or therapeutic treatment of cataract that acts by a different mechanism from conventional agents, use of a PPAR activator for production of the agent or the composition, and a novel ophthalmic agent.
  • a PPAR activator in other words, PPAR agonist
  • PPAR agonist enables prevention and therapeutic treatment of cataract, and accomplished the present invention.
  • an embodiment of the present invention includes the following features.
  • an agent for prevention and/or therapeutic treatment of cataract that acts by a different mechanism from conventional agents
  • a pharmaceutical composition for prevention and/or therapeutic treatment of cataract that acts by a different mechanism from conventional compositions
  • use of a PPAR activator for production of the agent or the composition and a novel ophthalmic agent.
  • Fig. 1 is a model diagram showing an example of an action mechanism of an agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention.
  • FIG. 2 show the effects, on cataract, of an agent for prevention and/or therapeutic treatment of cataract in accordance with an Example of the present invention.
  • the inventors of the present invention have conducted a study into cataract with use of ex-vivo diabetic cataract models using galactose-containing media. However, the inventors could not elucidate the mechanism by which galactose causes cataract or the mechanism by which galactose increases the severity of cataract.
  • galactose may cause and/or increase the severity of cataract by the mechanism schematically shown in Fig. 1 .
  • galactose induces apoptosis first, and the apoptosis causes and/or increases the severity of cataract.
  • a peroxisome proliferator-activated receptor plays an important role with regard to apoptosis in an aspect in which the apoptosis causes and/or increases the severity of cataract, and demonstrated that cataract can be prevented and therapeutically treated by a PPAR activator as described later in Examples.
  • the inventors thus accomplished the present invention.
  • the term "cataract” refers to a disease that creates an opaque (e.g., milky) area in the crystalline lens.
  • examples of the type of opacity that is caused by cataract in the crystalline lens include: cortical opacity (CO); nuclear opacity (NO); posterior subcapsular opacity (PSO); cortical spoke (CS); anterior subcapsular opacity (ASC); fiber folds (FF), waterclefts (WC), and perinuclear retrodots (RD); vacuoles (VC); focal dots (FD); and coronary flakes (CF).
  • cataract includes, for example, age-related cataract (senile cataract), congenital cataract, and complicated cataract (e.g., diabetic cataract, traumatic cataract, atopic cataract, radiation cataract, and steroid cataract).
  • diabetes refers to opacity of the crystalline lens developed in a patient of a disease characterized by continuous high glucose levels in blood or blood plasma (such a disease is, for example, hyperglycemia or diabetes (e.g., type I diabetes or type II diabetes)).
  • a disease is, for example, hyperglycemia or diabetes (e.g., type I diabetes or type II diabetes)).
  • diabetes e.g., type I diabetes or type II diabetes
  • preventive agent refers to an agent that provides a preventive effect.
  • preventive effect refers to, but is not limited to, any one or more of the effects listed below as examples.
  • one or more symptoms of a disease may be systemic or local.
  • therapeutic agent refers to an agent that provides a therapeutic effect.
  • therapeutic effect refers to, but is not limited to, any one or more of the effects listed below as examples.
  • one or more symptoms of a disease may be systemic or local.
  • the term "agent for prevention and/or therapeutic treatment” refers to an agent that serves as at least one of the preventive agent and the therapeutic agent and that provides any of the above-listed effects.
  • the “agent for prevention and/or therapeutic treatment” can be reworded as “treatment agent”.
  • the term “pharmaceutical composition for prevention and/or therapeutic treatment” can be reworded as "pharmaceutical composition for treatment”
  • the term “medicament for prevention and/or therapeutic treatment” can be reworded as "medicament for treatment”
  • the term “method for prevention and/or therapeutic treatment” can be reworded as "method of treatment”
  • the term “use in prevention and/or therapeutic treatment” can be reworded as "use in treatment”.
  • a PPAR activator (in other words, PPAR agonist) is a substance that activates a peroxisome proliferator-activated receptor (PPAR) and upregulates PPAR signaling pathway.
  • PPAR activator is a compound that binds to a PPAR and thereby provides an agonist effect.
  • the PPAR activator is also called "PPAR agonist".
  • There are subtypes of PPAR specifically, PPAR- ⁇ , PPAR- ⁇ , PPAR- ⁇ , PPAR- ⁇ , and PPAR- ⁇ ).
  • a PPAR activated by a PPAR activator in accordance with the present embodiment may be of any subtype.
  • the PPAR activator in accordance with the present embodiment may be PPAR- ⁇ activator, PPAR- ⁇ activator, PPAR- ⁇ activator, or PPAR- ⁇ activator.
  • the PPAR activator in accordance with the present embodiment may be a PPAR dual agonist (dual PPAR activator which activates a plurality of PPAR subtypes concurrently) or a pan-PPAR activator (PPAR activator that has low specificity and that activates PPAR subtypes concurrently in a uniform manner).
  • the agonist effect may be full agonist effect or partial agonist effect.
  • the PPAR activator in accordance with the present embodiment may be a fibrate, a thiazolidine, a glitazone, a glitazar, propionic acid, a terpene (e.g., monoterpene, sesquiterpene, diterpene, triterpene, steroid, or carotenoid), a polyketide (e.g., anthraquinone or prenylated polyketide), a phenylpropanoid (e.g., coumarin, lignan, or tannin), a polyphenol (e.g., chalcone, stilbene, flavonoid, isoflavonoid, or biflavonoid), or an alkaloid.
  • a terpene e.g., monoterpene, sesquiterpene, diterpene, triterpene, steroid, or carotenoid
  • a polyketide e.g., anthra
  • the PPAR activator in accordance with the present embodiment is at least one selected from the group consisting of fibrates, thiazolidines, glitazones, and glitazars. It is even more preferable that the PPAR activator in accordance with the present embodiment is at least one selected from the group consisting of fibrates and thiazolidines.
  • each substance's data consists of "(a) Name of the substance", "(b) IUPAC name of the substance”, “(c) PPAR subtype targeted by the substance”, “(d) Classification 1 of the substance”, and “(e) Classification 2 of the substance”. Also note that, in the following list, the symbol "-" means that there are no appropriate data or that the substance is difficult to classify.
  • the PPAR activator is more preferably bezafibrate, fenofibrate, ciprofibrate, clofibrate, rosiglitazone, pioglitazone, gemfibrozil, or etofibrate, and is even more preferably rosiglitazone, ciprofibrate, or gemfibrozil.
  • any of the above-listed PPAR activators may be used alone or two or more of them may be used in combination.
  • such one or more tautomers are also included within the scope of the PPAR activator in accordance with the present embodiment.
  • crystal polymorph systems for the PPAR activator in accordance with the present embodiment, such one or more crystal polymorphs and/or one or more crystal polymorph groups (crystal polymorph systems) are also included within the scope of the PPAR activator in accordance with the present embodiment.
  • crystal polymorph groups (crystal polymorph system) is, in a case where a crystal form changes variously depending on the conditions and/or states in which crystals are, for example, produced, crystallized, or preserved (note that those "states” also include formulated states), a generic term for "crystalline forms appearing in a specific stage and/or crystalline forms appearing in every stage".
  • a derivative of or a salt of any of the foregoing substances may be used as the PPAR activator.
  • Use of a derivative of or a salt of any of the foregoing substances provides the following effects, for example: (1) the preventive effect and/or therapeutic effect on cataract can be increased; (2) safety of a substance to the human body can be increased; and (3) a formulation can be prepared using a substance that is easy to handle.
  • derivative of a specific compound refers to any of compounds derived from that specific compound as a result of substitution of a part of the molecule of the specific compound with some other functional group or some other atom.
  • Examples of such other functional group include alkyl groups, alkoxy groups, alkylthio groups, aryl groups, aryloxy groups, arylthio groups, arylalkyl groups, arylalkoxy groups, arylalkylthio groups, arylalkenyl groups, arylalkyny groups, allyl group, amino groups, substituted amino groups, silyl groups, substituted silyl groups, silyloxy group, substituted silyloxy groups, arylsulfonyloxy groups, alkylsulfonyloxy groups, nitro group, and the like.
  • Examples of such other atom include carbon atom, hydrogen atom, oxygen atom, nitrogen atom, sulfur atom, phosphorus atom, halogen atoms, and the like.
  • salt refers to a salt that is physiologically acceptable to a subject.
  • the salt include alkali metal salts (such as lithium salt, sodium salt, potassium salt), alkaline earth metal salts (such as calcium salt, magnesium salt), metal salts (such as salts of any of the foregoing substances and iron, zinc, or the like), salts of any of the foregoing substances and ammonia, quaternary ammonium salts (such as salts of any of the foregoing substances and methyl bromide, methyl iodide, or the like), salts of any of the foregoing substances and halide ion (such as salts of any of the foregoing substances and bromide ion, chloride ion, iodide ion, or the like), organic basic salts (such as trimethylamine salt, triethylamine salt, triethylenediamine salt, 2-aminoethanol salt, pyridine salt, picoline salt, dicyclohexylamine
  • the foregoing PPAR activator can be produced in accordance with a known method.
  • a commercially available PPAR activator can be used as the foregoing PPAR activator.
  • An agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention contains the foregoing PPAR activator as an active ingredient.
  • the following description will discuss the agent for prevention and/or therapeutic treatment of cataract in accordance with the present embodiment.
  • an agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention is administered to a subject.
  • the subject is a human.
  • the subject is an animal other than human. Examples of the animal other than human include non-human mammals (such as cattle, swine, sheep, goats, horses, dogs, cats, rabbits, mice, rats).
  • the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention can be administered to a subject via any pharmaceutically acceptable route of administration.
  • routes of administration include peroral administration, parenteral administration, transdermal administration, transmucosal administration, and intravenous administration.
  • the dosage form of the agent for prevention and/or therapeutic treatment of cataract can be an internal medicine (agent for internal use), external medicine (agent for external administration), injection, suppository, inhalant, ophthalmic agent, or the like.
  • parenteral administration and transdermal administration are preferred, administration by instillation to an eye, intra-conjunctival sac administration, intracameral administration, intravitreal administration, subconjunctival administration, transdermal administration, and sub-Tenon's capsule administration are more preferred, and administration by instillation to an eye is even more preferred.
  • ophthalmic agent, ointment, cream, gel, transdermal formulation, adhesive skin patch, and injection are preferred, and ophthalmic agent is more preferred.
  • the ophthalmic agent may be in the form of water-based eye drops obtained by dissolving an agent in water or in the form of a suspension or emulsion.
  • ophthalmic agent is preferred are, for example, as follows: the route through which the active ingredient is delivered to the crystalline lens is short; other organs are less likely to be stimulated; almost no invasion is caused; systemic effect is small (application of pressure on lacrimal point after instillation further reduces the systemic effect); administration is easy; repetitive administration is available; a patient is able to self-care; and the like. According to the above arrangement, the preventive effect or therapeutic effect on cataract can be further accelerated and further increased.
  • the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention contains a PPAR activator as an active ingredient.
  • active ingredient refers to a substance that is capable of providing a preventive effect on one or more symptoms and/or a therapeutic effect on one or more symptoms.
  • the concentration of the PPAR activator contained in the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention can vary depending on the type of PPAR activator, route of administration of the agent for prevention and/or therapeutic treatment, dosage form of the agent for prevention and/or therapeutic treatment, and/or the like.
  • the concentration of the PPAR activator in the agent for prevention and/or therapeutic treatment is, for example, 0.001 ⁇ M or more, 0.002 ⁇ M or more, 0.005 ⁇ M or more, 0.01 ⁇ M or more, 0.02 ⁇ M or more, 0.05 ⁇ M or more, 0.1 ⁇ M or more, 0.2 ⁇ M or more, 0.5 ⁇ M or more, 1 ⁇ M or more, 2 ⁇ M or more, 3 ⁇ M or more, 4 ⁇ M or more, 5 ⁇ M or more, 6 ⁇ M or more, 7 ⁇ M or more, 8 ⁇ M or more, 9 ⁇ M or more, 10 ⁇ M or more, 20 ⁇ M or more, 30 ⁇ M or more, 40 ⁇ M or more, 50 ⁇ M or more, 60 ⁇ M or more, 70 ⁇ M or more, 80 ⁇ M or more, 90 ⁇ M or more, 100 ⁇ M or more, 200 ⁇ M or more, 300 ⁇ M or more, 400 ⁇ M or
  • the concentration of the PPAR activator in the agent for prevention and/or therapeutic treatment is, for example, 0.01 ⁇ M or less, 0.02 ⁇ M or less, 0.05 ⁇ M or less, 0.1 ⁇ M or less, 0.2 ⁇ M or less, 0.5 ⁇ M or less, 1 ⁇ M or less, 2 ⁇ M or less, 3 ⁇ M or less, 4 ⁇ M or less, 5 ⁇ M or less, 6 ⁇ M or less, 7 ⁇ M or less, 8 ⁇ M or less, 9 ⁇ M or less, 10 ⁇ M or less, 20 ⁇ M or less, 30 ⁇ M or less, 40 ⁇ M or less, 50 ⁇ M or less, 60 ⁇ M or less, 70 ⁇ M or less, 80 ⁇ M or less, 90 ⁇ M or less, 100 ⁇ M or less, 200 ⁇ M or less, 300 ⁇ M or less, 400 ⁇ M or less, 500 ⁇ M or less, 600 ⁇ M or less, 700 ⁇ M or less, 800 ⁇ M
  • the concentration of the PPAR activator in the agent for prevention and/or therapeutic treatment is, for example, 0.001 ⁇ M to 5000 ⁇ M, 0.001 ⁇ M to 0.01 ⁇ M, 0.002 ⁇ M to 0.02 ⁇ M, 0.005 ⁇ M to 0.05 ⁇ M, 0.01 ⁇ M to 0.1 ⁇ M, 0.02 ⁇ M to 0.2 ⁇ M, 0.05 ⁇ M to 0.5 ⁇ M, 0.1 ⁇ M to 1 ⁇ M, 0.2 ⁇ M to 2 ⁇ M, 0.3 ⁇ M to 3 ⁇ M, 0.4 ⁇ M to 4 ⁇ M, 0.5 ⁇ M to 5 ⁇ M, 0.6 ⁇ M to 6 ⁇ M, 0.7 ⁇ M to 7 ⁇ M, 0.8 ⁇ M to 8 ⁇ M, 0.9 ⁇ M to 9 ⁇ M, 1 ⁇ M to 10 ⁇ M, 2 ⁇ M to 20 ⁇ M, 3 ⁇ M to 30 ⁇ M, 4 ⁇ M to 40 ⁇ M, 5
  • the unit “M” means the amount-of-substance (mol) of a component per 1 L liquid, and may alternatively be expressed in the unit “mol/L".
  • the unit “M” means the amount-of-substance (mol) of a component per 1L of the ophthalmic agent.
  • a value expressed in the unit “M” is the amount-of-substance of the salt per 1 L liquid.
  • a value expressed in the unit "M" is the amount-of-substance of the hydrate or solvate per 1 L liquid. The same applies to other forms of substance, unless otherwise specified herein.
  • the concentration of the PPAR activator in the agent for prevention and/or therapeutic treatment is, for example, preferably 0.001 to 10% (w/v), more preferably 0.005 to 5% (w/v), even more preferably 0.01 to 2% (w/v), even more preferably 0.1 to 1% (w/v).
  • the concentration of ciprofibrate in the ophthalmic agent is preferably 0.001 to 10% (w/v), more preferably 0.005 to 5% (w/v), even more preferably 0.01 to 2% (w/v), even more preferably 0.1 to 1% (w/v).
  • the concentration of gemfibrozil in the ophthalmic agent is preferably 0.001 to 10% (w/v), more preferably 0.005 to 5% (w/v), even more preferably 0.01 to 2% (w/v), even more preferably 0.1 to 1% (w/v).
  • the concentration of rosiglitazone in the ophthalmic agent is preferably 0.001 to 10% (w/v), more preferably 0.005 to 5% (w/v), even more preferably 0.01 to 2% (w/v), even more preferably 0.1 to 1% (w/v).
  • the unit “% (w/v)” means the mass (g) of a component contained in 100 mL liquid.
  • the unit “% (w/v)” means the mass (g) of a component contained in 100 mL of the ophthalmic agent.
  • a value expressed in the unit “% (w/v)” means the amount of the salt contained in 100 mL liquid.
  • a value expressed in the unit "% (w/v)" means the amount of the hydrate or solvate of the substance contained in 100 mL liquid. The same applies to other forms of substance, unless otherwise specified herein.
  • the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention may further contain an active ingredient other than PPAR activators or may contain a PPAR activator as the only active ingredient.
  • the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention may further contain one or more additives for medicaments, optionally in order to satisfy the requirements for pharmaceutical formulation.
  • additives for medicaments include buffers, pH adjustors, tonicity agents, antiseptic agents, antioxidants, high molecular weight polymers, filler, carriers, diluents, solvents, solubilizing agents, stabilizers, bulking agents, binders, surfactants, stabilizing agents, and the like. Any of such additives may be used alone or two or more of them may be used in combination. The amount of such one or more additives may be selected appropriately.
  • Examples of the buffers include phosphoric acid, phosphates, boric acid, borates, citric acid, citrates, acetic acid, acetates, carbonic acid, carbonates, tartaric acid, tartrates, ⁇ -aminocaproic acid, trometamol, and the like.
  • Examples of the phosphates include sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and the like.
  • Examples of the borates include borax, sodium borate, potassium borate, and the like.
  • Examples of the citrates include sodium citrate, disodium citrate, trisodium citrate, and the like.
  • Examples of the acetates include sodium acetate, potassium acetate, and the like.
  • Examples of the carbonates include sodium carbonate, sodium hydrogen carbonate, and the like.
  • Examples of the tartrates include sodium tartrate, potassium tartrate, and the like.
  • pH adjustors examples include hydrochloric acid, phosphoric acid, citric acid, acetic acid, sodium hydroxide, potassium hydroxide, and the like.
  • tonicity agents examples include ionic tonicity agents (such as sodium chloride, potassium chloride, calcium chloride, and magnesium chloride) and nonionic tonicity agents (such as glycerin, propylene glycol, trometamol, sorbitol, and mannitol).
  • ionic tonicity agents such as sodium chloride, potassium chloride, calcium chloride, and magnesium chloride
  • nonionic tonicity agents such as glycerin, propylene glycol, trometamol, sorbitol, and mannitol.
  • antiseptic agents examples include benzalkonium chloride, benzalkonium bromide, benzethonium chloride, sorbic acid, potassium sorbate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, chlorhexidine gluconate, chlorobutanol, and the like.
  • antioxidants examples include ascorbic acid, tocopherol, dibutylhydroxytoluene, butylated hydroxyanisole, sodium erythorbate, propyl gallate, sodium sulfite, and the like.
  • high molecular weight polymers examples include methyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, carboxymethylcellulose sodium salt, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethyl ethyl cellulose, cellulose acetate phthalate, polyvinylpyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, polyethylene glycol, atelocollagen, and the like.
  • the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention preferably contains atelocollagen. According to the above arrangement, the preventive effect or therapeutic effect on cataract can be further accelerated and further increased.
  • the concentration of one or more additives contained in the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention is not particularly limited.
  • the concentration of one or more additives in the agent for prevention and/or therapeutic treatment may be, for example, 0 ⁇ M, 0.001 ⁇ M to 5000 ⁇ M, 0.001 to 0.01 ⁇ M, 0.002 to 0.02 ⁇ M, 0.005 to 0.05 ⁇ M, 0.01 to 0.1 ⁇ M, 0.02 to 0.2 ⁇ M, 0.05 to 0.5 ⁇ M, 0.1 to 1 ⁇ M, 0.2 to 2 ⁇ M, 0.3 to 3 ⁇ M, 0.4 to 4 ⁇ M, 0.5 to 5 ⁇ M, 0.6 to 6 ⁇ M, 0.7 to 7 ⁇ M, 0.8 to 8 ⁇ M, 0.9 to 9 ⁇ M, 1 to 10 ⁇ M, 2 to 20 ⁇ M, 3 to 30 ⁇ M, 4 to 40 ⁇ M, 5 to 50 ⁇ M, 6 to 60 ⁇ M, 7 to
  • the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention is, for example, an ophthalmic agent
  • the components contained in the ophthalmic agent may be totally dissolved or may be partially suspended. It is preferable that the components contained in the ophthalmic agent are totally dissolved, and that the ophthalmic agent is in the form of liquid.
  • the dosing interval is, for example, once every hour to once every six months, preferably once every hour, once every two hours, once every three hours, once every six hours, once every twelve hours, once a day, twice a day, three times a day, four times a day, five times a day, six times a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once a month, once every two months, once every three months, once every four months, once every five months, once every six months, more preferably at least once a day, at least once every two days, at least once every three days, at least once every four days, at least once every five days, at least once every six days, at least once every once every six days, at least once
  • the agent for prevention and/or therapeutic treatment of cataract in accordance with an embodiment of the present invention may be prescribed in combination with some other agent for prevention or therapeutic treatment of cataract and/or some other disease.
  • the present invention is directed to a pharmaceutical composition for prevention and/or therapeutic treatment of cataract, the pharmaceutical composition containing a PPAR activator as an active ingredient.
  • Another aspect of the present invention is directed to use of a PPAR activator for production of a medicament for prevention and/or therapeutic treatment of cataract (agent for prevention and/or therapeutic treatment of cataract).
  • a further aspect of the present invention is directed to a method for prevention and/or therapeutic treatment of cataract, the method including using a PPAR activator.
  • Still a further aspect of the present invention is directed to a method for prevention and/or therapeutic treatment of cataract, the method including the step of administering, to a subject, an agent for prevention and/or therapeutic treatment of cataract containing a PPAR activator as an active ingredient.
  • Still a further aspect of the present invention is directed to a PPAR activator for use in prevention and/or therapeutic treatment of cataract.
  • the scope of the present invention also includes (i) an ophthalmic agent containing ciprofibrate as an active ingredient (e.g., the concentration of ciprofibrate is 0.001 to 10% (w/v)), (ii) an ophthalmic agent containing gemfibrozil as an active ingredient (e.g., the concentration of gemfibrozil is 0.001 to 10% (w/v)), and (iii) an ophthalmic agent containing rosiglitazone as an active ingredient (e.g., the concentration of rosiglitazone is 0.001 to 10% (w/v)).
  • Such ophthalmic agents may be used for prevention and/or therapeutic treatment of cataract or may be used for some other purpose.
  • various conditions including the type of PPAR activator, how the PPAR activator is administered, administration route of the PPAR activator, subject who receives administration of the PPAR activator, dosage of the PPAR activator, and the like can be the same as those concerning the "agent for prevention and/or therapeutic treatment of cataract".
  • Example 1 effects of each agent were tested with use of ex-vivo diabetic cataract models using galactose-containing media.
  • the crystalline lenses were isolated from the right and left eyeballs of a 6-week-old SD rat (available from Sankyo Labo Service Corporation).
  • the isolated crystalline lenses were cultured with use of a medium obtained by adding 30 mM of galactose to an M199 medium (available from SIGMA). After that, the crystalline lenses were cultured with use of a medium obtained by adding 30 mM of galactose and 800 ⁇ M of a PPAR activator (specifically, bezafibrate or fenofibrate) to an M199 medium.
  • a PPAR activator specifically, bezafibrate or fenofibrate
  • a PPAR activator was added to the medium, and the culture of the crystalline lenses was restarted. 3 days after the restart of the culture, the crystalline lenses were removed from the medium and observed by microscopy under the SZX12 microscope (available from Olympas).
  • Fig. 2 shows the results obtained by microscopy. Note that (A) of Fig. 2 shows the results of the tests on bezafibrate, whereas (B) of Fig. 2 shows the results of the tests on fenofibrate. Also note that, in (A) and (B) of Fig. 2 , each of the legends "Day 3" indicates an image of a crystalline lens obtained 3 days after the start of the culture thereof using the medium obtained by adding 30 mM of galactose to an M199 medium (available from SIGMA), whereas each of the legends "Day 6" indicates an image of the crystalline lens obtained 3 days after the restart of the culture.
  • the isolated crystalline lens has experienced progress of opacity of the cortex from the start of the culture to 3 days after the culture.
  • the crystalline lens which had been cultured again using a medium having a PPAR activator added thereto, had a decreased degree of opacity of the cortex 3 days after the restart of the culture.
  • Example 2 effects of each agent were tested with use of ex-vivo diabetic cataract models using galactose-containing media, in a similar manner to Example 1.
  • the crystalline lenses were isolated from the right and left eyeballs of a 6-week-old SD rat (available from Sankyo Labo Service Corporation).
  • the isolated crystalline lenses were cultured with use of a medium obtained by adding 30 mM of galactose to an M199 medium (available from SIGMA). After that, the crystalline lenses were cultured with use of a medium obtained by adding 30 mM of galactose and a PPAR activator to an M199 medium.
  • a PPAR activator was added to the medium, and the culture of the crystalline lenses was restarted. 3 days after the restart of the culture, the crystalline lenses were removed from the medium and observed again by microscopy under the microscope SZX12 (available from Olympas). Note that, for the purpose of clarifying the effects of the PPAR activator, control crystalline lenses were cultured again using a medium having no PPAR activators added thereto.
  • the images obtained by the microscopy were imported into image processing software (Image J), and the number of pixels was analyzed. In this way, the total area of the crystalline lens and the area of the opaque area were calculated.
  • Table 1 shows (i) how the percentage of opacity of the crystalline lens changed when the type of PPAR activator and its concentration were changed and (ii) how the percentage of opacity of the crystalline lens changed in a case where the crystalline lens was cultured again using a medium with no PPAR activators added thereto (control).
  • Example 3 effects of each agent were tested with use of in-vivo diabetic cataract models raised on galactose feed.
  • a 3-week-old SD rat (available from Sankyo Labo Service Corporation) was raised for 1 week on feed containing 25% galactose.
  • ophthalmic agents were administered by instillation to both eyes of the rat every day (four times a day).
  • the components of the ophthalmic agents were as follows: dimethyl sulfoxide (DMSO; administered as a control) for the right eye; and DMSO containing a PPAR activator for the left eye.
  • DMSO dimethyl sulfoxide
  • the crystalline lenses were isolated from the right and left eyes of the rat, and observed by microscopy.
  • the type of PPAR activator administered to the left eye and its concentration in Example 3 are as follows. Ciprofibrate 200 mM Etofibrate 140 mM Gemfibrozil 200 mM Pioglitazone 200 mM Rosiglitazone 200 mM
  • the present invention is usable for an agent for prevention and/or therapeutic treatment of cataract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP18893830.2A 2017-12-28 2018-12-27 Agent prophylactique et/ou agent thérapeutique contre la cataracte, composition médicinale pour prévenir et/ou traiter la cataracte, utilisation d'un activateur de ppar pour produire ces derniers, et collyre Withdrawn EP3733203A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017254614 2017-12-28
PCT/JP2018/048211 WO2019131897A1 (fr) 2017-12-28 2018-12-27 Agent prophylactique et/ou agent thérapeutique contre la cataracte, composition médicinale pour prévenir et/ou traiter la cataracte, utilisation d'un activateur de ppar pour produire ces derniers, et collyre

Publications (2)

Publication Number Publication Date
EP3733203A1 true EP3733203A1 (fr) 2020-11-04
EP3733203A4 EP3733203A4 (fr) 2021-08-25

Family

ID=67067494

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18893830.2A Withdrawn EP3733203A4 (fr) 2017-12-28 2018-12-27 Agent prophylactique et/ou agent thérapeutique contre la cataracte, composition médicinale pour prévenir et/ou traiter la cataracte, utilisation d'un activateur de ppar pour produire ces derniers, et collyre

Country Status (9)

Country Link
US (1) US20210059997A1 (fr)
EP (1) EP3733203A4 (fr)
JP (1) JP7253805B2 (fr)
KR (1) KR20200105491A (fr)
CN (1) CN111511402A (fr)
CA (1) CA3086828A1 (fr)
RU (1) RU2020124373A (fr)
TW (1) TW201934529A (fr)
WO (1) WO2019131897A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4142795A4 (fr) * 2020-04-27 2024-05-22 The Research Institute at Nationwide Children's Hospital Agonistes de ppar? pour le traitement d'une maladie rénale
CN116744936A (zh) * 2020-11-17 2023-09-12 株式会社林原 晶状体硬度调节剂
WO2022107886A1 (fr) * 2020-11-19 2022-05-27 学校法人日本大学 Gouttes oculaires pour atténuer ou prévenir une perturbation circulatoire rétinienne et des troubles associés aux vaisseaux sanguins du nerf rétinien
KR102808692B1 (ko) * 2022-07-19 2025-05-21 주식회사 노브메타파마 에너지 대사 개선을 위한 ppar 작용제의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (fr) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
WO2000007582A2 (fr) * 1998-08-06 2000-02-17 Warner-Lambert Company Utilisation de derives de thiazolidinedione pour le traitement ou la prevention de cataractes
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
US20050004225A1 (en) * 2003-04-16 2005-01-06 Balendiran Ganesaratnam K. Oxidoreductase inhibitors and methods of screening and using thereof

Also Published As

Publication number Publication date
JP7253805B2 (ja) 2023-04-07
CA3086828A1 (fr) 2019-07-04
RU2020124373A (ru) 2022-01-28
EP3733203A4 (fr) 2021-08-25
JPWO2019131897A1 (ja) 2020-12-10
US20210059997A1 (en) 2021-03-04
TW201934529A (zh) 2019-09-01
KR20200105491A (ko) 2020-09-07
WO2019131897A1 (fr) 2019-07-04
CN111511402A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
EP3733203A1 (fr) Agent prophylactique et/ou agent thérapeutique contre la cataracte, composition médicinale pour prévenir et/ou traiter la cataracte, utilisation d'un activateur de ppar pour produire ces derniers, et collyre
CN102844023B (zh) Cdc7激酶抑制剂以及其用途
US6316465B1 (en) Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists
JP5536229B2 (ja) Ｈｃｖ併用療法
Yang et al. Protective effects of IRG1/itaconate on acute colitis through the inhibition of gasdermins-mediated pyroptosis and inflammation response
MXPA01005598A (es) Metodo y composicion para el tratamiento de cancer que utiliza aceites esenciales vegetales naturales con moduladores de transduccion de senal.
EP2939539A1 (fr) Compositions et procédés pharmaceutiques d'acide lipoïque a faible dose
US6500813B1 (en) Ophthalmic composition containing active vitamin D
CA2445963A1 (fr) Utilisation de flavones polymethoxylees afin de traiter l'insulinoresistance
JP2004516257A (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
PT1345598E (pt) A utilização de rosiglitazona para o tratamento de perturbações psiquiátricas
AU2018206907A1 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
US8962687B2 (en) Method of treating liver disorders
US20230068969A1 (en) Method to prevent and treat macular degeneration by calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers
HK40031660A (en) Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedrops
HK40029503A (en) Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedrops
JPWO2018079149A1 (ja) 白内障の予防剤、治療剤、およびこれらを製造するためのｈａｔ阻害剤の使用
JPWO2014104064A1 (ja) 創傷治癒促進剤
KR20120099366A (ko) 장기간 ｎｓａｉｄ 사용을 위한 약제
WO2024019661A1 (fr) Composés à base de labdane et utilisations de ceux-ci
KR102739882B1 (ko) 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물
US20230121797A1 (en) A combination of flavonoids and sphingosine 1 phosphate lyase inhibitors for the treatment of lung inflammation
EA004772B1 (ru) Применение 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона для уменьшения постишемического повреждения сердца
JPH0813739B2 (ja) 白内障治療剤
WO2023230375A1 (fr) Cannabinoïdes pour le traitement d'une neuro-inflammation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031660

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/00 20060101AFI20210702BHEP

Ipc: A61K 31/192 20060101ALI20210702BHEP

Ipc: A61K 31/216 20060101ALI20210702BHEP

Ipc: A61K 31/4178 20060101ALI20210702BHEP

Ipc: A61P 3/10 20060101ALI20210702BHEP

Ipc: A61P 27/12 20060101ALI20210702BHEP

Ipc: A61P 43/00 20060101ALI20210702BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210723

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/00 20060101AFI20210719BHEP

Ipc: A61K 31/192 20060101ALI20210719BHEP

Ipc: A61K 31/216 20060101ALI20210719BHEP

Ipc: A61K 31/4178 20060101ALI20210719BHEP

Ipc: A61P 3/10 20060101ALI20210719BHEP

Ipc: A61P 27/12 20060101ALI20210719BHEP

Ipc: A61P 43/00 20060101ALI20210719BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220222